Prolyl Carboxypeptidase Maintains Receptor Tyrosine Kinase Signaling and Is a Potential Therapeutic Target in Triple Negative Breast Cancer

SIMPLE SUMMARY: Triple negative breast cancer (TNBC) is an aggressive cancer type with limited treatment options and poor prognosis. Our research has revealed that a protein called prolylcarboxypeptidase (PRCP) is a potential therapy target for TNBC. We found that high levels of PRCP in tumors coinc...

Descripción completa

Detalles Bibliográficos
Autores principales: Duan, Lei, Calhoun, Sarah, Perez, Ricardo E., Macias, Virgilia, Mir, Fatima, Pergande, Melissa R., Gattuso, Paolo, Borgia, Jeffrey A., Maki, Carl G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833515/
https://www.ncbi.nlm.nih.gov/pubmed/35159006
http://dx.doi.org/10.3390/cancers14030739

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833515/
https://www.ncbi.nlm.nih.gov/pubmed/35159006
http://dx.doi.org/10.3390/cancers14030739

Ejemplares similares